Search
beta-Hydroxybutyric acid
go.drugbank.com/drugs/DB16506InvestigationalBeta-hydroxybutyrate is being studied in around 230 clinical trials, including NCT06351124 (recruiting for Crohn's disease), NCT05584371 (recruiting for safety and tolerability of exogenous ketosis), NCT04656236
Pirlindole
go.drugbank.com/drugs/DB09244ExperimentalThis drug is classified as a reversible inhibitor of monoamine oxidase A enzyme (also known as a RIMA drug). It was developed and is currently used as an antidepressant in Russia. … The antidepressant efficacy and safety of pirlindole have been demonstrated in numerous studies and, supported by many years of clinical experience in the treatment of depression.
Urea
go.drugbank.com/drugs/DB03904ApprovedInvestigationalA compound formed in the liver from ammonia produced by the deamination of amino acids. … It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids.
Edonerpic
go.drugbank.com/drugs/DB05938InvestigationalEdonerpic is a neurotrophic agent intended for the treatment of Alzheimer's disease which is under phase I clinical trial.
AZD 3355
go.drugbank.com/drugs/DB05404InvestigationalAZD 3355 is a reflux inhibitor used for the treatment of Gastroesophageal Reflux Disease. It is developed by AstraZeneca and is currently in phase I/II trials.
Progabide
go.drugbank.com/drugs/DB00837ExperimentalProgabide is an analog and prodrug of gamma-aminobutyric acid. It is commonly used in the treatment of epilepsy. It has agonistic activity for both the GABAA and GABAB receptors. … In clinical trials, progabide has been investigated for Parkinson's disease, schizophrenia, clinical depression and anxiety disorder; its therapeutic effectiveness in these conditions is not fully elucidated
Calanolide A
go.drugbank.com/drugs/DB04886InvestigationalCalanolide A is a new non-nucleoside reverse transcriptase inhibitor (NNRTI) derived from a plant found in the Malaysian rain forest. A related compound, calanolide B, also has anti-HIV activity.
Rimtuzalcap
go.drugbank.com/drugs/DB16733InvestigationalRimtuzalcap is a novel modulator of small-conductance calcium-activated potassium channels that is under investigation for the treatment of essential tremor.[L38414]
Synonyms: N-(4,4-difluorocyclohexyl)-2-(3-methyl-1H-pyrazol-1-yl)-6-morpholinopyrimidin-4-amine(-)-menthol 1-propylene glycol carbonate
go.drugbank.com/drugs/DB14136InvestigationalMixtures: Thera Derm Roll On